目的:探讨岩藻多糖对胰腺癌的影响,并分析其机制。方法:MTT法分析细胞增殖抑制率,GEPIA数据库分析G3BP1在胰腺癌组织中的表达水平及与生存率的关系。qRT-PCR分析GTP酶激活蛋白结合蛋白1(Ras-GTPase-activating protein binding proteins...目的:探讨岩藻多糖对胰腺癌的影响,并分析其机制。方法:MTT法分析细胞增殖抑制率,GEPIA数据库分析G3BP1在胰腺癌组织中的表达水平及与生存率的关系。qRT-PCR分析GTP酶激活蛋白结合蛋白1(Ras-GTPase-activating protein binding proteins,G3BP1)水平,Western blot法分析p-NF-κBp65、NF-κBp65和IκB-α水平。免疫共沉淀检测G3BP1与p-NF-κBp65之间相互作用。敲低或G3BP1过表达,观察其对岩藻多糖调控细胞增殖以及NF-κB信号通路的影响。裸鼠成瘤实验验证岩藻多糖对裸鼠体内瘤体的瘤重、瘤体积及G3BP1、p-NF-κBp65、NF-κBp65和IκBα水平的影响。结果:1~32μg/mL岩藻多糖抑制capan-1细胞增殖,岩藻多糖48 h IC_(50)为7.729μg/mL。G3BP1在胰腺癌肿瘤组织中的表达明显高于正常组织,G3BP1高表达患者的生存率低于G3BP1低表达患者。2、4、8μg/mL岩藻多糖能下调G3BP1、p-NF-κBp65,上调IκBα水平。Co-IP实验发现G3BP1与p-NF-κBp65相互结合,并且岩藻多糖作用后结合能力降低。敲低G3BP1能促进岩藻多糖抑制capan-1细胞增殖,下调G3BP1、p-NF-κBp65,上调IκBα水平(P<0.05);G3BP过表达能下调岩藻多糖抑制capan-1细胞增殖效果,上调G3BP1、p-NF-κBp65,下调IκBα水平(P<0.05)。体内实验显示,敲低G3BP1能促进岩藻多糖减少瘤体体积、瘤体质量,下调瘤体G3BP1、p-NF-κBp65,上调IκBα水平(P<0.05)。结论:岩藻多糖抑制capan-1细胞增殖,对体内移植瘤抑瘤效果显著,其机制与调控G3BP1/NF-κB信号通路有关。展开更多
目的ATP结合盒B亚家族成员1(ATP binding cassette subfamily B member 1,ABCB1)的异常表达在多种癌症的发生发展中发挥关键作用。然而,G蛋白偶联受体C家族5组A型(G protein coupled receptor family C group5 type A,GPRC5A)调控的ABCB...目的ATP结合盒B亚家族成员1(ATP binding cassette subfamily B member 1,ABCB1)的异常表达在多种癌症的发生发展中发挥关键作用。然而,G蛋白偶联受体C家族5组A型(G protein coupled receptor family C group5 type A,GPRC5A)调控的ABCB1表达对肺腺癌增殖的影响仍不清楚。本研究探讨了GPRC5A调控的ABCB1表达对肺腺癌增殖的影响。方法我们采用RT-PCR、Western-blot或免疫组化实验,分析ABCB1在肺腺癌细胞系、人肺腺癌组织以及GPRC5A基因敲除小鼠和野生型小鼠的气管上皮细胞和肺组织中的表达。采用细胞计数试剂盒-8(CCK-8)分析GPRC5A基因敲除小鼠气管上皮细胞对化疗药物的敏感性。采用皮下肿瘤形成实验探讨下调ABCB1表达是否可抑制体内肺腺癌增殖。采用免疫荧光和免疫沉淀实验研究GPRC5A和ABCB1之间潜在的调控关系。结果ABCB1在肺腺癌细胞系和人类肺腺癌组织中表达上调。GPRC5A基因敲除小鼠的气管上皮细胞及肺组织的ABCB1表达高于野生型小鼠。与GPRC5A野生型小鼠的气管上皮细胞相比,GPRC5A基因敲除小鼠的气管上皮细胞对塔立奇达和多柔比星更敏感。注射移植细胞28天后,接受ABCB1基因敲除细胞移植的GPRC5A-/-C57BL/6小鼠的肺肿瘤的体积和重量均明显低于野生型细胞移植小鼠(P=0.0043,P=0.0060)。此外,免疫荧光和免疫沉淀实验表明,GPRC5A通过直接结合方式调控ABCB1的表达。结论GPRC5A通过抑制ABCB1表达降低肺腺癌增殖。GPRC5A调节ABCB1表达的途径有待研究。展开更多
Fexofenadine is useful in various allergic disease treatment.However,the pharmacokinetic variability information and quantitative factor identification of fexofenadine are very lacking.This study aimed to verify the v...Fexofenadine is useful in various allergic disease treatment.However,the pharmacokinetic variability information and quantitative factor identification of fexofenadine are very lacking.This study aimed to verify the validity of previously proposed genetic factors through fexofenadine population pharmacokinetic modeling and to explore the quantitative correlations affecting the pharmacokinetic variability.Polymorphisms of the organic-anion-transporting-polypeptide(OATP)1B1 and 2B1 have been proposed to be closely related to fexofenadine pharmacokinetic diversity.Therefore,modeling was performed using fexofenadine oral exposure data according to the OATP1B1-and 2B1-polymorphisms.OATP1B1 and 2B1 were identified as effective covariates of clearance(CL/F)and distribution volume(V/F)-CL/F,respectively,in fexofenadine pharmacokinetic variability.CL/F and average steady-state plasma concentration of fexofenadine differed by up to 2.17-and 2.20-folds,respectively,depending on the OATP1B1 polymorphism.Among the individuals with different OATP2B1 polymorphisms,the CL/F and V/F differed by up to 1.73-and 2.00-folds,respectively.Ratio of the areas under the curves following single-and multiple-administrations,and the cumulative ratio were significantly different between OATP1B1-and 2B1-polymorphism groups.Based on quantitative prediction comparison through a model-based approach,OATP1B1 was confirmed to be relatively more important than 2B1 regarding the degree of effect on fexofenadine pharmacokinetic variability.Based on the established pharmacokineticpharmacodynamic relationship,the difference in fexofenadine efficacy according to genetic polymorphisms of OATP1B1 and 2B1 was 1.25-and 0.87-times,respectively,and genetic consideration of OATP1B1 was expected to be important in the pharmacodynamics area as well.This population pharmacometrics study will be a very useful starting point for fexofenadine precision medicine.展开更多
文摘目的:探讨岩藻多糖对胰腺癌的影响,并分析其机制。方法:MTT法分析细胞增殖抑制率,GEPIA数据库分析G3BP1在胰腺癌组织中的表达水平及与生存率的关系。qRT-PCR分析GTP酶激活蛋白结合蛋白1(Ras-GTPase-activating protein binding proteins,G3BP1)水平,Western blot法分析p-NF-κBp65、NF-κBp65和IκB-α水平。免疫共沉淀检测G3BP1与p-NF-κBp65之间相互作用。敲低或G3BP1过表达,观察其对岩藻多糖调控细胞增殖以及NF-κB信号通路的影响。裸鼠成瘤实验验证岩藻多糖对裸鼠体内瘤体的瘤重、瘤体积及G3BP1、p-NF-κBp65、NF-κBp65和IκBα水平的影响。结果:1~32μg/mL岩藻多糖抑制capan-1细胞增殖,岩藻多糖48 h IC_(50)为7.729μg/mL。G3BP1在胰腺癌肿瘤组织中的表达明显高于正常组织,G3BP1高表达患者的生存率低于G3BP1低表达患者。2、4、8μg/mL岩藻多糖能下调G3BP1、p-NF-κBp65,上调IκBα水平。Co-IP实验发现G3BP1与p-NF-κBp65相互结合,并且岩藻多糖作用后结合能力降低。敲低G3BP1能促进岩藻多糖抑制capan-1细胞增殖,下调G3BP1、p-NF-κBp65,上调IκBα水平(P<0.05);G3BP过表达能下调岩藻多糖抑制capan-1细胞增殖效果,上调G3BP1、p-NF-κBp65,下调IκBα水平(P<0.05)。体内实验显示,敲低G3BP1能促进岩藻多糖减少瘤体体积、瘤体质量,下调瘤体G3BP1、p-NF-κBp65,上调IκBα水平(P<0.05)。结论:岩藻多糖抑制capan-1细胞增殖,对体内移植瘤抑瘤效果显著,其机制与调控G3BP1/NF-κB信号通路有关。
文摘目的ATP结合盒B亚家族成员1(ATP binding cassette subfamily B member 1,ABCB1)的异常表达在多种癌症的发生发展中发挥关键作用。然而,G蛋白偶联受体C家族5组A型(G protein coupled receptor family C group5 type A,GPRC5A)调控的ABCB1表达对肺腺癌增殖的影响仍不清楚。本研究探讨了GPRC5A调控的ABCB1表达对肺腺癌增殖的影响。方法我们采用RT-PCR、Western-blot或免疫组化实验,分析ABCB1在肺腺癌细胞系、人肺腺癌组织以及GPRC5A基因敲除小鼠和野生型小鼠的气管上皮细胞和肺组织中的表达。采用细胞计数试剂盒-8(CCK-8)分析GPRC5A基因敲除小鼠气管上皮细胞对化疗药物的敏感性。采用皮下肿瘤形成实验探讨下调ABCB1表达是否可抑制体内肺腺癌增殖。采用免疫荧光和免疫沉淀实验研究GPRC5A和ABCB1之间潜在的调控关系。结果ABCB1在肺腺癌细胞系和人类肺腺癌组织中表达上调。GPRC5A基因敲除小鼠的气管上皮细胞及肺组织的ABCB1表达高于野生型小鼠。与GPRC5A野生型小鼠的气管上皮细胞相比,GPRC5A基因敲除小鼠的气管上皮细胞对塔立奇达和多柔比星更敏感。注射移植细胞28天后,接受ABCB1基因敲除细胞移植的GPRC5A-/-C57BL/6小鼠的肺肿瘤的体积和重量均明显低于野生型细胞移植小鼠(P=0.0043,P=0.0060)。此外,免疫荧光和免疫沉淀实验表明,GPRC5A通过直接结合方式调控ABCB1的表达。结论GPRC5A通过抑制ABCB1表达降低肺腺癌增殖。GPRC5A调节ABCB1表达的途径有待研究。
文摘Fexofenadine is useful in various allergic disease treatment.However,the pharmacokinetic variability information and quantitative factor identification of fexofenadine are very lacking.This study aimed to verify the validity of previously proposed genetic factors through fexofenadine population pharmacokinetic modeling and to explore the quantitative correlations affecting the pharmacokinetic variability.Polymorphisms of the organic-anion-transporting-polypeptide(OATP)1B1 and 2B1 have been proposed to be closely related to fexofenadine pharmacokinetic diversity.Therefore,modeling was performed using fexofenadine oral exposure data according to the OATP1B1-and 2B1-polymorphisms.OATP1B1 and 2B1 were identified as effective covariates of clearance(CL/F)and distribution volume(V/F)-CL/F,respectively,in fexofenadine pharmacokinetic variability.CL/F and average steady-state plasma concentration of fexofenadine differed by up to 2.17-and 2.20-folds,respectively,depending on the OATP1B1 polymorphism.Among the individuals with different OATP2B1 polymorphisms,the CL/F and V/F differed by up to 1.73-and 2.00-folds,respectively.Ratio of the areas under the curves following single-and multiple-administrations,and the cumulative ratio were significantly different between OATP1B1-and 2B1-polymorphism groups.Based on quantitative prediction comparison through a model-based approach,OATP1B1 was confirmed to be relatively more important than 2B1 regarding the degree of effect on fexofenadine pharmacokinetic variability.Based on the established pharmacokineticpharmacodynamic relationship,the difference in fexofenadine efficacy according to genetic polymorphisms of OATP1B1 and 2B1 was 1.25-and 0.87-times,respectively,and genetic consideration of OATP1B1 was expected to be important in the pharmacodynamics area as well.This population pharmacometrics study will be a very useful starting point for fexofenadine precision medicine.
